Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Status:
Withdrawn
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study is an extension study (prospective observational study) of 'IDEAL' study (A Study
to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular
Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase,
NCT02204722) to evaluate the duration of treatment response, disease progression, and
survival status up to 5 years after the inclusion.